11 September 2025
Mathematical and economic modelling for optimal strategies to screen and treat chronic hepatitis C virus patients using novel antiviral agents with cost-effectiveness and budget impact analyses in Thai setting
View Count
42
Share this research
Project Duration
Start : 1 April 2018
End : 30 April 2019
End : 30 April 2019
Research Status
Completed 100%
Complete Research Report
Quantity 0 files
Download Count
0 times
11 September 2025
Mathematical and economic modelling for optimal strategies to screen and treat chronic hepatitis C virus patients using novel antiviral agents with cost-effectiveness and budget impact analyses in Thai setting
About Project
Content
Chronic hepatitis C virus (HCV) infection is a major cause of cirrhosis, end-stage liver disease and hepatocellular carcinoma (HCC). It has been calculated that 130-170 million people are infected with HCV, with a global prevalence of infection estimated at 2%-3%. Approximately 75%-85% of people infected with HCV will develop chronic hepatitis, 60%-70% will develop hepatic steatosis or fibrosis, 5%-20% will develop cirrhosis and in 1%-5% disease will progress to life-threatening complications and HCC, within 20 years from acute infection. Despite the great successes achieved in the fields of virology and diagnostics, several difficulties affect improvements in hepatitis C virus (HCV) infection control and eradication in the new era. New HCV infections still occur, especially in some of the poorest regions of the world, where HCV is endemic and long-term sequelae have a growing economic and health burden. This study aims to perform cost-effectiveness analysis of potential screening and treatment allocation strategies for chronic hepatitis C infections focusing on novel antiviral drugs in Thailand as well as to determine the feasibility of the new treatment policy by assessing human resource on health impact and budget impact using mathematical modelling approach. The findings will be useful for guiding the drug price negotiation and treatment allocation strategy to yield maximum benefit at individual and society levels.
Research Type
Others
Related Technologies
Pharmaceuticals
Funding Source
Mahidol-Oxford Tropical Medicine Research Unit (MORU)
Cluster and Program Management Office, National Science and Technology Development Agency (NSTDA)
Research Team
Principal Researcher
Related Organizations/
Supporting Organizations
Mahidol-Oxford Tropical Medicine Research Unit (MORU)
Cluster and Program Management Office, National Science and Technology Development Agency (NSTDA)